Cancer patients test easier blood thinner dose to stop deadly clots
NCT ID NCT07005024
Summary
This study aims to find the best way to use a common blood thinner (apixaban) to prevent dangerous blood clots in cancer patients who are at moderate risk. About 1,000 patients starting cancer treatment will be randomly assigned to take the standard twice-daily dose, a new once-daily dose, or no blood thinner at all. Researchers will track who develops clots, has serious bleeding, or dies over six months to see if the simpler once-daily dose works as well and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.